Semaglutide is intentionally started at a low dose and gradually increased over several weeks to months, allowing the gastrointestinal system time to adapt
Results From August 2020 to August 2024, 4,463 patients were approached, with 1,454 (32.6%) enrolled, a rate that stayed consistent across these years
Since patients with HF with New York Heart Association class IV were excluded from the CVOTs, it is unclear whether safety risks could occur in semaglutide-treated patients
"These patients are at risk when using these untested and illegal products," Landers echoes
"Like if that doesn't scream high-risk behaviour to you, I'm not sure what does." If peptides were effective, pharmaceutical companies would patent and sell the medications, Phillips said
The connection is thought to be related to the weight loss itself, rather than a direct effect of the medication